The tweet was deleted by the author.
But we saved everything 🙂.
Accuray reports that the Carlo Besta Neurological Institute has achieved disease stability in patients with non-functioning pituitary adenoma using multi-session radiosurgery with the CyberKnife system.
The study found no radiological progression in treated patients, with preservation of visual function and limited toxicity observed. This approach may provide a valuable treatment alternative for patients with residual or recurrent pituitary adenoma, expanding options in precision radiotherapy and radiosurgery.
Accuray previously unveiled PRO-FAST, a single-day prostate radiotherapy protocol using CyberKnife, at ESTRO26 in Milan. An Accuray study also found CyberKnife treatment achieved full local control with a strong safety profile in 68 uveal melanoma patients at ISRS2026. These studies highlight ongoing clinical evaluation of CyberKnife in diverse indications.